Biomarker-based trials in neuro-oncology

Karla V. Ballman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Treatment of brain tumors is increasingly informed by biomarkers. One use is to appropriately group tumors with similar genetic/genomic characteristics and to design trials separately for the individual groups. The biomarker's use is to predict patient response so that the most effective treatment can be selected for patients based on their tumor characteristics. Trial designs that recruit unselected patients are poorly suited for identifying treatments effective only in subsets of patients given the relatively small numbers of patients available for trials. Investigators are beginning to use different designs that better account for tumor heterogeneity. In this article, an overview of the role of biomarkers in brain tumor trials is presented in the context of existing clinical trials as well as trials that may be launched within the next several years.

Original languageEnglish (US)
Article number38
JournalChinese Clinical Oncology
Volume4
Issue number3
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Biomarkers
Brain Neoplasms
Neoplasms
Therapeutics
Research Personnel
Clinical Trials

Keywords

  • Biomarkers
  • Clinical trials
  • Neuro-oncology

ASJC Scopus subject areas

  • Oncology

Cite this

Biomarker-based trials in neuro-oncology. / Ballman, Karla V.

In: Chinese Clinical Oncology, Vol. 4, No. 3, 38, 2015.

Research output: Contribution to journalArticle

Ballman, Karla V. / Biomarker-based trials in neuro-oncology. In: Chinese Clinical Oncology. 2015 ; Vol. 4, No. 3.
@article{8bcbd6997677446b855cd4e00dded3af,
title = "Biomarker-based trials in neuro-oncology",
abstract = "Treatment of brain tumors is increasingly informed by biomarkers. One use is to appropriately group tumors with similar genetic/genomic characteristics and to design trials separately for the individual groups. The biomarker's use is to predict patient response so that the most effective treatment can be selected for patients based on their tumor characteristics. Trial designs that recruit unselected patients are poorly suited for identifying treatments effective only in subsets of patients given the relatively small numbers of patients available for trials. Investigators are beginning to use different designs that better account for tumor heterogeneity. In this article, an overview of the role of biomarkers in brain tumor trials is presented in the context of existing clinical trials as well as trials that may be launched within the next several years.",
keywords = "Biomarkers, Clinical trials, Neuro-oncology",
author = "Ballman, {Karla V.}",
year = "2015",
doi = "10.3978/j.issn.2304-3865.2015.09.04",
language = "English (US)",
volume = "4",
journal = "Chinese Clinical Oncology",
issn = "2304-3865",
publisher = "Society for Translational Medicine (STM)",
number = "3",

}

TY - JOUR

T1 - Biomarker-based trials in neuro-oncology

AU - Ballman, Karla V.

PY - 2015

Y1 - 2015

N2 - Treatment of brain tumors is increasingly informed by biomarkers. One use is to appropriately group tumors with similar genetic/genomic characteristics and to design trials separately for the individual groups. The biomarker's use is to predict patient response so that the most effective treatment can be selected for patients based on their tumor characteristics. Trial designs that recruit unselected patients are poorly suited for identifying treatments effective only in subsets of patients given the relatively small numbers of patients available for trials. Investigators are beginning to use different designs that better account for tumor heterogeneity. In this article, an overview of the role of biomarkers in brain tumor trials is presented in the context of existing clinical trials as well as trials that may be launched within the next several years.

AB - Treatment of brain tumors is increasingly informed by biomarkers. One use is to appropriately group tumors with similar genetic/genomic characteristics and to design trials separately for the individual groups. The biomarker's use is to predict patient response so that the most effective treatment can be selected for patients based on their tumor characteristics. Trial designs that recruit unselected patients are poorly suited for identifying treatments effective only in subsets of patients given the relatively small numbers of patients available for trials. Investigators are beginning to use different designs that better account for tumor heterogeneity. In this article, an overview of the role of biomarkers in brain tumor trials is presented in the context of existing clinical trials as well as trials that may be launched within the next several years.

KW - Biomarkers

KW - Clinical trials

KW - Neuro-oncology

UR - http://www.scopus.com/inward/record.url?scp=84960339592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960339592&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2304-3865.2015.09.04

DO - 10.3978/j.issn.2304-3865.2015.09.04

M3 - Article

VL - 4

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 3

M1 - 38

ER -